Durable complete responses from therapy with combined epratuzumab and rituximab: Final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Lymphoma, Non-Hodgkin
  • Neoplasm Recurrence, Local

abstract

  • The combination of epratuzumab and rituximab induced durable responses in patients with recurrent, indolent NHL.

publication date

  • November 15, 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.23890

PubMed ID

  • 18853418

Additional Document Info

start page

  • 2714

end page

  • 23

volume

  • 113

number

  • 10